Mass COVID-19 patient screening using UvsX and UvsY mediated DNA recombination and high throughput parallel sequencing

• Published in: Scientific reports Vol. 12; no. 1; p. 4082
• Main Authors: Palmieri, Dario, Javorina, Amanda, Siddiqui, Jalal, Gardner, Anne, Fries, Anthony, Chapleau, Richard R., Starr, Clarise, Fishel, Richard, Miles, Wayne O.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.03.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/1647/2163; 692/420/254; Bioinformatics; Coronaviruses; Cough; COVID-19; COVID-19 - diagnosis; COVID-19 - virology; DNA sequencing; DNA-Binding Proteins - metabolism; Fever; Genomes; High-Throughput Nucleotide Sequencing; Humanities and Social Sciences; Humans; Mass Screening; Membrane Proteins - metabolism; multidisciplinary; Next-generation sequencing; Nucleic Acid Amplification Techniques - methods; Patients; Recombinase; Recombination; RNA viruses; RNA, Viral - analysis; RNA, Viral - metabolism; SARS-CoV-2 - genetics; SARS-CoV-2 - isolation & purification; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Viral Proteins - metabolism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-08034-1

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), is a highly infectious RNA virus. A percentage of patients develop coronavirus disease 2019 (COVID-19) after infection, whose symptoms include fever, cough, shortness of breath and fatigue. Acute and life-threatening respiratory symptoms are experienced by 10–20% of symptomatic patients, particularly those with underlying medical conditions. One of the main challenges in the containment of COVID-19 is the identification and isolation of asymptomatic/pre-symptomatic individuals. A number of molecular assays are currently used to detect SARS-CoV-2. Many of them can accurately test hundreds or even thousands of patients every day. However, there are presently no testing platforms that enable more than 10,000 tests per day. Here, we describe the foundation for the REcombinase Mediated BaRcoding and AmplificatioN Diagnostic Tool (REMBRANDT), a high-throughput Next Generation Sequencing-based approach for the simultaneous screening of over 100,000 samples per day. The REMBRANDT protocol includes direct two-barcoded amplification of SARS-CoV-2 and control amplicons using an isothermal reaction, and the downstream library preparation for Illumina sequencing and bioinformatics analysis. This protocol represents a potentially powerful approach for community screening of COVID-19 that may be modified for application to any infectious or non-infectious genome.